Comparative Pharmacology
Head-to-head clinical analysis: DEXASPORIN versus METICORTELONE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DEXASPORIN versus METICORTELONE.
DEXASPORIN vs METICORTELONE
Head-to-head clinical comparison of therapeutic indices and safety profiles.
Dexasporin is a synthetic corticosteroid with potent anti-inflammatory and immunosuppressive properties. It binds to the glucocorticoid receptor, leading to modulation of gene expression and inhibition of pro-inflammatory mediators such as prostaglandins and leukotrienes.
Corticosteroid with glucocorticoid and mineralocorticoid activity; binds to glucocorticoid receptors, modulating gene expression to suppress inflammation and immune response.
Allergic reactionsInflammatory conditions (e.g., arthritis, dermatitis)Immunosuppression in organ transplantationAdjunctive therapy in severe COVID-19
Allergic conditionsDermatologic diseasesEndocrine disordersGastrointestinal diseasesHematologic disordersNeoplastic diseasesNervous system disordersOphthalmic diseasesRenal diseasesRespiratory diseasesRheumatic disorders
1 to 2 mg/kg intramuscular or intravenous every 8 hours.
Prednisolone: 5-60 mg orally once daily or divided twice daily; methylprednisolone: 4-48 mg orally once daily or divided twice daily. Dose and duration vary by indication.
None Documented
None Documented
3-4 hours (prolonged to 10-15 hours in renal impairment; monitor CrCl <30 mL/min)
Terminal elimination half-life: 3.0-3.5 hours; clinical context: requires multiple daily doses for sustained effect; biological half-life (duration of HPA suppression) longer (~24-36 hours) due to intracellular activity
Primarily hepatic via CYP3A4 isoenzymes; metabolites are excreted renally.
Hepatic via CYP3A4; primarily metabolized to inactive metabolites.
Renal excretion (80-90% unchanged), biliary/fecal (10-20%)
Renal: <5% unchanged; hepatic metabolism to inactive metabolites, primarily conjugated and excreted in urine; <2% fecal
25-40% (albumin)
75-80% bound, primarily to corticosteroid-binding globulin (CBG, transcortin) and albumin
0.2-0.3 L/kg (primarily extracellular fluid; moderate tissue penetration)
0.5-1.0 L/kg; clinical meaning: moderate tissue distribution, indicating extensive extravascular distribution and high tissue penetration
IM: 100%; oral: not available (must be parenteral)
Oral: approximately 80-90% (well absorbed); IM: 100%
CrCl > 50 mL/min: no adjustment; CrCl 10-50 mL/min: 50% of usual dose every 12 hours; CrCl < 10 mL/min: 25% of usual dose every 24 hours.
No specific GFR-based adjustment required; caution in severe renal impairment due to fluid retention.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50%; Child-Pugh C: avoid use.
Child-Pugh A: No adjustment. Child-Pugh B: Reduce dose by 50%. Child-Pugh C: Reduce dose by 75% or consider alternative.
Neonates: 10 mg/kg IV every 12 hours; Infants and children: 1.5 mg/kg IV every 8 hours, maximum 100 mg/dose.
0.14-2 mg/kg/day orally divided every 6-12 hours; maximum 60 mg/day. Use lowest effective dose.
Initiate at lower end of dosing range; adjust based on renal function; monitor for neurotoxicity and ototoxicity.
Start at lowest effective dose; monitor for osteoporosis, hypertension, hyperglycemia, and immunosuppression. Use minimum duration.
Long-term use may lead to adrenal suppression and increased risk of infections. Avoid abrupt discontinuation.
None.
["May mask signs of infection","Increased risk of osteoporosis with prolonged use","Monitor for hyperglycemia","Caution in patients with hypertension or heart failure due to fluid retention"]
Adrenal suppression with prolonged use; increased susceptibility to infections; masking of infection signs; osteoporosis; glaucoma; cataracts; Cushing's syndrome; growth suppression in children; psychiatric disturbances; cardiovascular effects (hypertension, fluid retention); gastrointestinal perforation risk.
["Systemic fungal infections","Hypersensitivity to dexasporin or any component","Administration of live vaccines during therapy"]
Systemic fungal infections; hypersensitivity to corticosteroids; administration of live or live-attenuated vaccines in patients receiving immunosuppressive doses.
Data Pending Review
Data Pending Review
Avoid excessive intake of potassium-rich foods (e.g., bananas, oranges, tomatoes, spinach, salt substitutes) due to spironolactone's potassium-sparing effect. Grapefruit juice may alter dexamethasone metabolism; avoid concurrent use. Limit sodium to reduce edema.
Avoid excessive salt intake due to potential sodium retention. Grapefruit and grapefruit juice may increase drug levels; use caution. Concurrent use with potassium-depleting diuretics may worsen hypokalemia; consider potassium-rich foods if needed.
DEXASPORIN is contraindicated in pregnancy due to established teratogenicity. First trimester exposure associated with neural tube defects and cardiovascular malformations. Second and third trimester exposure may cause fetal growth restriction and preterm birth.
Prednisolone (active metabolite of Meticortelone) crosses placenta but is largely inactivated by 11β-hydroxysteroid dehydrogenase type 2. First trimester: increased risk of cleft palate (odds ratio ~3.4) with high doses (>10-20 mg/day). Second/third trimesters: associated with fetal growth restriction, adrenal suppression, and preterm birth. Risk is dose- and duration-dependent.
DEXASPORIN is excreted in human milk; M/P ratio 0.8. Potential for infant immunosuppression; contraindicated during breastfeeding.
Prednisolone is excreted into breast milk in low concentrations (M/P ratio approximately 0.2-0.4). Maternal doses up to 40 mg/day produce negligible infant exposure (<10% of maternal dose). Avoid high-dose or prolonged therapy; consider timing doses after breastfeeding to minimize exposure.
No established safe dose; contraindicated in pregnancy. Pharmacokinetic changes in pregnancy include increased clearance and volume of distribution, but no adjustment is recommended due to risk.
No routine dose adjustment required due to pregnancy-induced pharmacokinetic changes. Prednisolone clearance modestly increases in late pregnancy; however, therapeutic effect is maintained. Titrate to lowest effective dose for disease control. Consider stress-dose coverage during labor if on chronic therapy (>20 mg/day for >3 weeks).
Category C
Category C
Dexasporin is a combination of dexamethasone (glucocorticoid) and spironolactone (potassium-sparing diuretic). Use with caution in hepatic impairment; monitor serum potassium and renal function. Avoid in Addison's disease or hyperkalemia. May mask signs of infection. Taper glucocorticoid dose to avoid adrenal insufficiency. Spironolactone may cause gynecomastia and menstrual irregularities.
Meticortelone (prednisolone) is a glucocorticoid with 4-5 times the anti-inflammatory potency of hydrocortisone and minimal mineralocorticoid activity. Use with caution in patients with diabetes, hypertension, or osteoporosis. Taper dose to avoid adrenal insufficiency. Monitor for signs of infection, as immunosuppression may mask symptoms. Long-term use requires calcium and vitamin D supplementation.
Take with food or milk to reduce gastrointestinal irritation.Do not stop dexamethasone abruptly; follow physician's tapering schedule.Report sudden weight gain, edema, muscle weakness, or black stools.Avoid potassium supplements and high-potassium foods unless directed.Limit sodium intake to minimize fluid retention.Use caution with NSAIDs or aspirin due to increased GI risk.May cause dizziness; avoid driving if affected.
Take with food or milk to reduce gastrointestinal upset.Do not stop abruptly; follow the doctor's tapering schedule to avoid withdrawal symptoms.Inform all healthcare providers that you are taking this medication.Avoid exposure to infections; report any fever, sore throat, or unusual bruising.Monitor blood sugar if diabetic, as prednisolone may increase glucose levels.Use caution with nonsteroidal anti-inflammatory drugs (NSAIDs) to reduce risk of gastrointestinal bleeding.